Submission of Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has submitted a routine compliance certificate to BSE for the quarter ended 31 March 2025. The certificate was issued by its Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Pvt Ltd, under SEBI's Depository Regulations. It confirms that all share certificates received for dematerialisation were properly cancelled and that the company's name was updated as the registered owner in NSDL and CDSL records within the required 15-day window. The filing was signed by Whole-time Director Venkateshwarlu Pulluru. This is a standard procedural submission with no operational or financial information disclosed.
No impact on shareholders or stock price. This is a routine quarterly compliance filing required of all listed companies and carries no material business information.